Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00476385 | Practicability and Acceptability of Stylomax® in Children | PHASE3 | COMPLETED | 12 | — | — | Jun 1, 2003 | - | Feb 12, 2009 | 1 | France |
| Arm | Type | Description |
|---|---|---|
| somatropine | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| somatropine | DRUG | subcutaneous injections, 20 % less than the dosage of Maxomat 1.3 mg |
Inclusion Criteria: * Children over 3 years of age with growth hormone deficiency, requiring treatment with MAXOMAT® according to the criteria of the MA. Exclusion Criteria: * The above information is not intended to contain all considerations relevant to a patient's potential participation in a ...